Quad Pharmaceuticals
Executive Summary
FDA has approved the firm's ANDA suitability petitions for floxuridine 500 mg/5 ml injection ready to use solution; cytarabine injection ready to use, 20 mg/ml in 5 ml (non-preserved) single use vials and 25 ml (preserved) multiple dose vials; and dacarbazine 500 mg/vial (lyophilized) for injection.